CIC
MRNA icon

Carnegie Investment Counsel’s Moderna MRNA Stock Holding History

Carnegie Investment Counsel’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,990
Closed -$306K – 508
2023
Q1 		$306K Buy
+1,990
New +$328K 0.01% 432
2021
Q4 		– Sell
-950
Closed -$366K – 509
2021
Q3 		$366K Sell
950
-1,400
-60% -$516K 0.01% 362
2021
Q2 		$552K Sell
2,350
-650
-22% -$116K 0.02% 316
2021
Q1 		$393K Hold
3,000
– – 0.02% 344
2020
Q4 		$313K Sell
3,000
-3,950
-57% -$400K 0.01% 355
2020
Q3 		$492K Buy
6,950
+2,528
+57% +$176K 0.03% 286
2020
Q2 		$284K Buy
+4,422
New +$242K 0.02% 350

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Carnegie Investment Counsel's MRNA Position: Q2 2023 in Review

Carnegie Investment Counsel sold out of Moderna (MRNA) in Q2 2023, closing a stake of 1,990 shares — an estimated $306K sold.

Carnegie Investment Counsel first reported a position in MRNA in Q2 2020 and held it in 7 quarters. The position peaked at $552K in Q2 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Carnegie Investment Counsel reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Carnegie Investment Counsel sold 1,990 Moderna shares in Q2 2023, an estimated $306K.
  • Carnegie Investment Counsel first reported a position in Moderna in Q2 2020 and held it in 7 quarters.
  • Carnegie Investment Counsel's Moderna position peaked at $552K in Q2 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Carnegie Investment Counsel's 13F filing for Q2 2023, filed 4 Aug 2023.